Identification of novel microRNAs negatively regulating cardiac hypertrophy

Jeong, Moon Hee; Lee, Jong Sub; Kim, Do Han; Park, Woo Jin; Yang, Dong Kwon

doi:10.1016/j.bbrc.2012.10.040

Cited by 12 publications

(12 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Five miRNAs (miR-101b, -142-3p, -181d, -24-2*, and -450a) were identified as negative regulators of cardiac hypertrophy, since they abrogated the phenylephedrine (PE)-induced hypertrophy in neonatal rat cardiomyocytes, and transfection of antagomirs for these miRNAs significantly exacerbated PE-induced hypertrophic responses [148]. …”

Section: Micrornas In Age-related Cardiovascular Diseasesmentioning

confidence: 99%

MicroRNAs Expression Profiles in Cardiovascular Diseases

Bronze-da-Rocha

2014

BioMed Research International

149

117

View full text Add to dashboard Cite

The current search for new markers of cardiovascular diseases (CVDs) is explained by the high morbidity and mortality still observed in developed and developing countries due to cardiovascular events. Recently, microRNAs (miRNAs or miRs) have emerged as potential new biomarkers and are small sequences of RNAs that regulate gene expression at posttranscriptional level by inhibiting translation or inducing degradation of the target mRNAs. Circulating miRNAs are involved in the regulation of signaling pathways associated to aging and can be used as novel diagnostic markers for acute and chronic diseases such as cardiovascular pathologies. This review summarizes the biogenesis, maturation, and stability of miRNAs and their use as potential biomarkers for coronary artery disease (CAD), myocardial infarction (MI), and heart failure (HF).

show abstract

Section: Micrornas In Age-related Cardiovascular Diseasesmentioning

confidence: 99%

MicroRNAs Expression Profiles in Cardiovascular Diseases

Bronze-da-Rocha

2014

BioMed Research International

149

117

View full text Add to dashboard Cite

show abstract

“…miR-142-3p might be implicated in various cardiovascular diseases in addition to PAH, such as cardiac hypertrophy, heart failure and cardiac arrhythmias. miRNA expression profiling studies using a cardiac hypertrophy-regression surgical model have shown that miR-142-3p negatively regulates cardiac hypertrophy, although the mechanism underlying the anti-hypertrophic effects has not yet been elucidated [Jeong et al, 2012]. miR-142-3p might target genes controlling cell survival and differentiation as well as DOCK6, as cardiac hypertrophy is promoted by inhibiting the expression of genes involved in cell survival and differentiation.…”

Section: Discussionmentioning

confidence: 99%

miR‐142‐3p Is a Regulator of the TGFβ‐Mediated Vascular Smooth Muscle Cell Phenotype

Kim

Yang

Kim

et al. 2015

J of Cellular Biochemistry

Self Cite

View full text Add to dashboard Cite

The transforming growth factor β (TGFβ) signaling pathway is critical for the promotion and maintenance of the contractile phenotype of vascular smooth muscle cells (VSMCs). Though multiple microRNAs (miRNAs) implicated in the regulation of the VSMC phenotype have been identified, the modulation of miRNAs in the VSMCs by TGFβ signaling has not been fully described. In this study, we identified microRNA-142-3p (miR-142-3p) as a modulator of the VSMC phenotype in response to TGFβ signaling. We show that miR-142-3p is induced upon TGFβ signaling, leading to the repression of a novel target, dedicator of cytokinesis 6 (DOCK6). The downregulation of DOCK6 by miR-142-3p is critical for cell migration. Thus, this study demonstrates that miR-142-3p is a key regulator of the TGFβ-mediated contractile phenotype of VSMCs that acts through inhibiting cell migration through targeting DOCK6.

show abstract

“…This miRNA is one of five negatively regulating cardiac hypertrophy in recent experimental models. Therefore, miR-142-3p is currently discussed as a part of potential therapeutic targets for the treatment of cardiac hypertrophy [92]. …”

Section: Discussionmentioning

confidence: 99%

Detection and comparison of microRNA expression in the serum of Doberman Pinschers with dilated cardiomyopathy and healthy controls

Steudemann

Bauersachs²,

Weber

et al. 2013

BMC Vet Res

View full text Add to dashboard Cite

BackgroundDilated cardiomyopathy (DCM) is the most common heart disease in Doberman Pinschers. MicroRNAs (miRNAs) are short non-coding RNAs playing important roles in gene regulation. Different miRNA expression patterns have been described for DCM in humans and might represent potential diagnostic markers. There are no studies investigating miRNA expression profiles in canine DCM. The aims of this study were to screen the miRNA expression profile of canine serum using miRNA microarray and to compare expression patterns of a group of Doberman Pinschers with DCM and healthy controls.ResultsEight Doberman Pinschers were examined by echocardiography and 24-hour-ECG and classified as healthy (n = 4) or suffering from DCM (n = 4). Total RNA was extracted from serum and hybridized on a custom-designed 8x60k miRNA microarray (Agilent) containing probes for 1368 individual miRNAs. Although total RNA concentrations were very low in serum samples, 404 different miRNAs were detectable with sufficient signal intensity on miRNA microarray. 22 miRNAs were differentially expressed in the two groups (p < 0.05 and fold change (FC) > 1.5), but did not reach statistical significance after multiple testing correction (false discovery rate adjusted p > 0.05). Five miRNAs were selected for further analysis using quantitative Real-Time RT-PCR (qPCR) assays. No significant differences were found using specific miRNA qPCR assays (p > 0.05).ConclusionsNumerous miRNAs can be detected in canine serum. Between healthy and DCM dogs, miRNA expression changes could be detected, but the results did not reach statistical significance most probably due to the small group size. miRNAs are potential new circulating biomarkers in veterinary medicine and should be investigated in larger patient groups and additional canine diseases.

show abstract

Identification of novel microRNAs negatively regulating cardiac hypertrophy

Cited by 12 publications

References 21 publications

MicroRNAs Expression Profiles in Cardiovascular Diseases

MicroRNAs Expression Profiles in Cardiovascular Diseases

miR‐142‐3p Is a Regulator of the TGFβ‐Mediated Vascular Smooth Muscle Cell Phenotype

Detection and comparison of microRNA expression in the serum of Doberman Pinschers with dilated cardiomyopathy and healthy controls

Contact Info

Product

Resources

About